Core Viewpoint - The company has issued a statement regarding the standards and developments related to recombinant collagen products, highlighting the need for continuous improvement in quality standards and testing methods to meet industry demands and consumer expectations [1][2]. Group 1: Industry Standards - In 2021, the guideline for naming recombinant collagen biomaterials was published and implemented [1] - In 2022, the pharmaceutical industry standard YY/T 1849-2022 for recombinant collagen was published and implemented [1] - In 2023, the pharmaceutical industry standard YY/T 1888-2023 for recombinant humanized collagen was published and implemented [1] - In 2023, the group standard T/ZGKSL 004-2023 for recombinant collagen raw materials used in cosmetics was published and implemented [1] - In 2025, the pharmaceutical industry standard YY/T 1947-2025 for recombinant collagen dressings is set to be published, with implementation in March 2026 [1] Group 2: Company Response and Actions - The company has conducted a comprehensive self-inspection of all aspects of production, testing, and labeling in response to recent discussions about the recombinant collagen content in its products [1] - The company acknowledges the limitations of its current quality standards, testing methods, and labeling, which need to be optimized to align with industry advancements and high consumer expectations [2] - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [2] - The company aims to gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [2] - The company will continue to participate in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized industry development [2]
巨子生物：公司现有质量标准、检测方法和标签标识已显现局限性，需要优化迭代